Drug Discovery

Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment

Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).

Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease

Eli Lilly has collaborated with Junshi Biosciences for the development of therapeutic antibodies to treat and prevent Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus.

Canada grants AbCellera $124m for research on Covid-19

AbCellera has secured a commitment of up to CAD175.6m ($124.3m) from the Government of Canada to discover solutions for Covid-19 and construct a manufacturing facility for antibody drugs.

Moderna and Lonza announce worldwide strategic collaboration to manufacture Moderna’s vaccine against novel coronavirus

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.

Default Table Multi-Parameter Transmitter M800

The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.

Quotient Sciences and CytoAgents accelerate potential treatment for COVID-19 cytokine storm

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.

Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers

Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.

Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies

Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.

Affinivax announces $120m Series B financing to advance pipeline of novel MAPS vaccines and immunotherapies

Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.